151 related articles for article (PubMed ID: 33738509)
21. Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant.
Sohn B; An C; Kim D; Ahn SS; Han K; Kim SH; Kang SG; Chang JH; Lee SK
J Neurooncol; 2021 Dec; 155(3):267-276. PubMed ID: 34648115
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features.
Ren Y; Zhang X; Rui W; Pang H; Qiu T; Wang J; Xie Q; Jin T; Zhang H; Chen H; Zhang Y; Lu H; Yao Z; Zhang J; Feng X
J Magn Reson Imaging; 2019 Mar; 49(3):808-817. PubMed ID: 30194745
[TBL] [Abstract][Full Text] [Related]
23. Can Dynamic Susceptibility Contrast Perfusion Imaging be Utilized to Detect Isocitrate Dehydrogenase Gene Mutation in Gliomas?
Kilincer A; Cebeci H; Seher N; Durmaz MS; Uysal E; Sahinoglu M; Koktekir E; Karabagli H; Karabagli P; Paksoy Y
Turk Neurosurg; 2022; 32(5):826-833. PubMed ID: 35713257
[TBL] [Abstract][Full Text] [Related]
24. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
[TBL] [Abstract][Full Text] [Related]
25. Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network.
Choi KS; Choi SH; Jeong B
Neuro Oncol; 2019 Sep; 21(9):1197-1209. PubMed ID: 31127834
[TBL] [Abstract][Full Text] [Related]
26. In vivo molecular profiling of human glioma using diffusion kurtosis imaging.
Hempel JM; Bisdas S; Schittenhelm J; Brendle C; Bender B; Wassmann H; Skardelly M; Tabatabai G; Vega SC; Ernemann U; Klose U
J Neurooncol; 2017 Jan; 131(1):93-101. PubMed ID: 27604789
[TBL] [Abstract][Full Text] [Related]
27. Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.
Hojjati M; Badve C; Garg V; Tatsuoka C; Rogers L; Sloan A; Faulhaber P; Ros PR; Wolansky LJ
J Neuroimaging; 2018 Jan; 28(1):118-125. PubMed ID: 28718993
[TBL] [Abstract][Full Text] [Related]
28. Association of dynamic susceptibility contrast- and dynamic contrast-enhanced magnetic resonance imaging parameters with molecular marker status in lower-grade gliomas: A retrospective study.
Ahn SH; Ahn SS; Park YW; Park CJ; Lee SK
Neuroradiol J; 2023 Feb; 36(1):49-58. PubMed ID: 35532193
[TBL] [Abstract][Full Text] [Related]
29. IDH1 mutation prediction using MR-based radiomics in glioblastoma: comparison between manual and fully automated deep learning-based approach of tumor segmentation.
Choi Y; Nam Y; Lee YS; Kim J; Ahn KJ; Jang J; Shin NY; Kim BS; Jeon SS
Eur J Radiol; 2020 Jul; 128():109031. PubMed ID: 32417712
[TBL] [Abstract][Full Text] [Related]
30. Diffusion and perfusion MR patterns of central nervous system lymphomas.
Neska-Matuszewska M; Zimny A; Bladowska J; Sąsiadek M
Adv Clin Exp Med; 2018 Aug; 27(8):1099-1108. PubMed ID: 29975467
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
[TBL] [Abstract][Full Text] [Related]
32. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
[TBL] [Abstract][Full Text] [Related]
33. Diffusion kurtosis imaging combined with molecular markers as a comprehensive approach to predict overall survival in patients with gliomas.
Wang X; Li F; Wang D; Zeng Q
Eur J Radiol; 2020 Jul; 128():108985. PubMed ID: 32361603
[TBL] [Abstract][Full Text] [Related]
34. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging.
She D; Xing Z; Cao D
J Comput Assist Tomogr; 2019; 43(1):13-17. PubMed ID: 30015801
[TBL] [Abstract][Full Text] [Related]
35. The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated
Choi YS; Ahn SS; Lee HJ; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
AJNR Am J Neuroradiol; 2017 Aug; 38(8):1528-1535. PubMed ID: 28642265
[TBL] [Abstract][Full Text] [Related]
36. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
[TBL] [Abstract][Full Text] [Related]
37. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.
Molenaar RJ; Verbaan D; Lamba S; Zanon C; Jeuken JW; Boots-Sprenger SH; Wesseling P; Hulsebos TJ; Troost D; van Tilborg AA; Leenstra S; Vandertop WP; Bardelli A; van Noorden CJ; Bleeker FE
Neuro Oncol; 2014 Sep; 16(9):1263-73. PubMed ID: 24510240
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
39. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
40. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]